Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.3813
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 210097880100.0
- FreeCF/Share 6.7321
- PFCF 12.3304
- PE 12.1469
- Debt/Assets 0.3027
- DivYield 0.0474
- ROE 0.3816
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
Read More
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
Read More
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
Read More
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Read More
Major deals involving U.S. drugmakers and biotechs over the past decade
Published: July 09, 2025 by: Reuters
Sentiment: Positive
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Read More
Undercovered Dozen: Roku, Merck, Chevron And More
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, INMune Bio, Nutex Health, LyondellBasell, Shopify, IBIT:CA and BITO are rated Strong Buy or Buy. MSTY is rated Hold.
Read More
Merck to Buy Verona Pharma for Around $10 Billion
Published: July 09, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Read More
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
Published: July 09, 2025 by: Schwab Network
Sentiment: Positive
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Read More
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Read More
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
Published: July 09, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Read More
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Published: July 09, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.
Read More
Merck & Co.: A Pharma Titan At A Discount
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its current market price, MRK is as much as 23% undervalued. Underlying fundamentals are still strong, with great margins, heavy R&D investing, and a plan to aggressively expand by CapEx spending totaling $20 billion from 2024 to 2028.
Read More
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.
Read More
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Read More
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.
Read More
Top 10 High-Yield Dividend Stocks For July 2025
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performing in-line with SPY and VYM, while providing a superior dividend yield. The June 2025 watchlist includes 10 stocks with an average forward dividend yield of 3.54% and an expected return of 13.62%.
Read More
Dividend Yield Theory Says Merck Is A Buy
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expiration and political headwinds, Merck's robust pipeline and adaptability offer a credible path to future growth. DYT analysis projects a 42%-83% total return over four years, with Merck meeting or exceeding most fundamental quality metrics.
Read More
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Published: June 27, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.
Read More
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
Read More
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Read More
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
Published: June 26, 2025 by: CNBC
Sentiment: Positive
Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus.
Read More
US CDC panel votes in favor of Merck's RSV antibody drug
Published: June 26, 2025 by: Reuters
Sentiment: Positive
An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mother did not receive a preventive shot during pregnancy.
Read More
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
Read More
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Read More
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clin.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Read More
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000